Archives
-
Oxidation Routes Shape Hazelnut Protein Gels
2026-09-16
The 2024 reference study shows that AAPH, malondialdehyde, and hydrogen peroxide do not produce interchangeable forms of hazelnut protein oxidation. By comparing functional properties with gel structure, it identifies oxidation chemistry as a major determinant of emulsification, water retention, foaming, and protein-network integrity.
-
Reparixin for CXCR1/2 Mechanism Studies
2026-09-16
Reparixin offers a receptor-level way to test whether IL-8–CXCR1/2 signaling links MRSA extracellular vesicles with oral cancer growth, while also supporting neutrophil migration and tissue-injury studies. This workflow combines pharmacological inhibition with EV comparisons, genetic controls, chemotaxis assays, and in vivo validation.
-
Dual-Metric Drug Response Testing in Cancer
2026-09-15
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but not interchangeable drug-response outcomes. This framework helps researchers interpret anticancer experiments more precisely by considering both response magnitude and timing, including studies of selective PLK1 inhibitors.
-
Salvianolic acid B: Pulmonary Fibrosis Workflows
2026-09-15
Translate the LH2–collagen axis into practical pulmonary fibrosis assays with Salvianolic acid B, from stock preparation through orthogonal ECM readouts. This workflow emphasizes dose design, matrix-specific controls, and troubleshooting for a reproducible natural product for fibrosis studies.
-
Porcupine Inhibition in Severe Sclerosteosis
2026-09-14
A 2025 Bone Research study tested the PORCN inhibitor LGK974 as a pharmacological strategy for excessive Wnt/β-catenin activity in SOST-deficient sclerosteosis. Cell and mouse experiments reduced osteoblast activity and pathological bone accumulation, while sex-dependent differences in Axin2 suppression highlighted the need for biomarker-guided translation.
-
MK-1775: Measure Checkpoint-Driven Cell Killing
2026-09-14
MK-1775 is a Wee1 kinase inhibitor that links G2 checkpoint abrogation to measurable changes in proliferation and cell death. This article presents an assay-interpretation framework that separates growth arrest from true cytotoxicity in p53-deficient tumor models.
-
WM-8014 for Reliable Cell Assay Interpretation
2026-09-13
WM-8014 (SKU A8779) is a reversible, competitive KAT6A/KAT6B inhibitor for investigating cell-cycle arrest, oncogene-induced senescence, and epigenetic dependencies. This scenario-based guide connects its biochemical potency, handling limits, and model-specific evidence to practical cell viability and proliferation workflows.
-
Crizotinib hydrochloride in Gastric Assembloids
2026-09-12
Crizotinib hydrochloride provides a mechanistic way to interrogate ALK, c-Met, and ROS1 signaling in patient-derived gastric cancer models. Pairing this ALK kinase inhibitor with matched tumor–stroma assembloids can reveal when microenvironmental context changes pathway engagement, viability responses, or apparent drug resistance.
-
PBS (Phosphate-Buffered Saline) Workflow Guide
2026-09-11
PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, ready-to-use isotonic buffer for cell washing, reagent dilution, and other routine in vitro workflows requiring controlled pH and osmolarity. It is intended for scientific research only and should not be used for diagnostic, clinical, medical, or in vivo applications.
-
G-1 and the Translational Logic of GPR30
2026-09-11
G-1 offers a selective way to interrogate rapid GPR30 signaling across immune, cardiovascular, and oncology models. This thought-leadership perspective connects receptor pharmacology with experimental design, evidence qualification, and translational decision-making.
-
Pexidartinib (PLX3397): Assay Workflow Guide
2026-09-10
This scenario-driven guide explains how Pexidartinib (PLX3397), SKU B5854, can support reproducible macrophage-focused viability, proliferation, and cytotoxicity experiments. It covers mechanism, solvent handling, dose design, interpretation of SPP1-related findings, and practical product-selection criteria.
-
α2-AR Agonists in Osteosarcoma Recurrence
2026-09-10
The reference study investigates local delivery of the α2-adrenergic receptor agonist UK14,304 after osteosarcoma resection, identifying an immune-mediated rather than directly cytotoxic mechanism. Its findings connect tumor control with CD8+ T-cell activation, T-cell receptor signaling, and ITGAL-centered regulation, while highlighting thermo-sensitive hydrogel delivery as a potentially useful research platform.
-
BPN-19186 in Nrf2 Signaling Workflows
2026-09-09
Build reproducible redox and osteoclastogenesis assays with BPN-19186, using controlled solvent handling, dose-ranging, and orthogonal Nrf2 readouts. The workflow connects small-molecule testing with the liver–bone axis described in recent osteoporosis research while clearly separating supported findings from exploratory applications.
-
Praeruptorin A Workflows for Inflammation Research
2026-09-09
Praeruptorin A is an angular pyranocoumarin compound suited to coordinated inflammation, ferroptosis, barrier, migration, and cardiomyopathy assays. This practical guide connects pathway-resolved readouts with formulation controls, concentration planning, and troubleshooting strategies for more reproducible translational experiments.
-
Latrunculin A for Actin–Virus Assays
2026-09-08
Latrunculin A converts actin perturbation into a controllable assay for cytoskeleton disaggregation, cell motility, and host–virus studies. This guide translates VP26–MYH9 findings into practical dose, timing, imaging, controls, and troubleshooting decisions.